P
Proof Diagnostics
Proof diagnostics is developing a crispr-based, covid-19 molecular test to help communities take control of the virus
About Proof Diagnostics
Proof Diagnostics is a healthcare startup that is developing a CRISPR-based COVID-19 molecular test. The company's primary goal is to make testing for COVID-19 simple, scalable, and reliable. The test, which is currently for investigational use only and has not yet been reviewed by the FDA, can deliver results in as little as 22 minutes. This is achieved through highly sensitive detection methods and gold-standard specificity.
The company is targeting a wide range of clients, including remote and underserved communities, schools, doctors' offices, employers, and hotels. The aim is to provide a quick and reliable method to confirm positive COVID-19 results, helping to keep communities, classrooms, and workplaces safe.
Proof Diagnostics is also developing automated workflows for clinicians by securely connecting with electronic health records (EHRs) and lab information management systems (LIMS). This will streamline the testing process and make it easier for healthcare providers to manage and track results.
In addition, the company is designing a mobile app that can connect with up to six Proof Lab readers via Bluetooth. This will allow users to monitor multiple COVID-19 tests, keep and view up to 50 results, and easily export detailed test results. The app is also being designed to enable third-party integrations, such as with EHRs.
Proof Diagnostics operates on a business model that involves selling low-cost reader and cartridges, making testing scalable. The company's equipment is small, modular, and portable, making it easy to set up and operate in various locations.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 59.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2024 | $0 | — | Ginkgo Bioworks | ↗ |
| SERIES A✓Equity / VC | Apr 2022 | $45M | $180M | ARCH Venture Partners · F-Prime · Madrona Venture Group | ↗ |
Growth signals
Latest recorded traffic for Proof Diagnostics is 1.3K monthly website visits, down 51.9% over the last three months. Proof Diagnostics's team declined 80% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A3 investors entered at this stage
Other known investors2 additional known investors
Ginkgo Bioworks
Sahsen Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Proof Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Proof Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











